Global Proton Pump Inhibitors Market Size, Share, Trends and Forecast 2022-2030

Description

Proton-pump inhibitors (PPIs) are a group of medications whose main action is a pronounced and long-lasting reduction of stomach acid production.
Proton pump inhibitors (PPIs) reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the esophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the esophagus, stomach, and duodenum to heal.

PPIs are among the most widely sold medications in the world. The class of proton-pump inhibitor medications is on the World Health Organization's List of Essential Medicines.

Medically used proton pump inhibitors: Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole.

Industry Insights

Due to the COVID-19 pandemic, the global Proton Pump Inhibitors market size is estimated to be worth US$ 12190 million in 2021 and is forecast to a readjusted size of US$ 9680.8 million by 2028 with a CAGR of -3.2% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Proton Pump Inhibitors market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Proton Pump Inhibitors landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Global Proton Pump Inhibitors key players include AstraZeneca, Takeda, etc. Global top two manufacturers hold a share over 15%.

North America is the largest market, with a share about 30%, followed by Asia-Pacific, and Europe, having a share about 50 percent.

In terms of product, Esomeprazole is the largest segment, with a share about 30%. And in terms of application, the largest application is Hospital Pharmacy, followed by Retail Pharmacy, etc.

This report focuses on Proton Pump Inhibitors volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Proton Pump Inhibitors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Israel, Japan, China and India, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Proton Pump Inhibitors market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

Dexlansoprazole

Esomeprazole

Lansoprazole

Omeprazole

Pantoprazole

Rabeprazole

Segment by Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Takeda

Pfizer

AstraZeneca

Bayer

Sun Pharma

Teva

Eisai Co.

Mylan

AOSAIKANG Pharma

Luoxin Pharma

LIVZON

Eastchina Pharma

TABLE OF CONTENT

1 Proton Pump Inhibitors Market Overview
1.1 Product Overview and Scope of Proton Pump Inhibitors

1.2 Proton Pump Inhibitors Segment by Type

1.2.1 Global Proton Pump Inhibitors Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 Dexlansoprazole

1.2.3 Esomeprazole

1.2.4 Lansoprazole

1.2.5 Omeprazole

1.2.6 Pantoprazole

1.2.7 Rabeprazole

1.3 Proton Pump Inhibitors Segment by Distribution Channel

1.3.1 Global Proton Pump Inhibitors Sales Comparison by Distribution Channel: (2022-2028)

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Others

1.4 Global Proton Pump Inhibitors Market Size Estimates and Forecasts

1.4.1 Global Proton Pump Inhibitors Revenue 2017-2028

1.4.2 Global Proton Pump Inhibitors Sales 2017-2028

1.4.3 Proton Pump Inhibitors Market Size by Region: 2017 Versus 2021 Versus 2028

2 Proton Pump Inhibitors Market Competition by Manufacturers

2.1 Global Proton Pump Inhibitors Sales Market Share by Manufacturers (2017-2022)

2.2 Global Proton Pump Inhibitors Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Proton Pump Inhibitors Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Proton Pump Inhibitors Manufacturing Sites, Area Served, Product Type

2.5 Proton Pump Inhibitors Market Competitive Situation and Trends

2.5.1 Proton Pump Inhibitors Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Proton Pump Inhibitors Players Market Share by Revenue

2.5.3 Global Proton Pump Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Proton Pump Inhibitors Retrospective Market Scenario by Region

3.1 Global Proton Pump Inhibitors Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Proton Pump Inhibitors Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Proton Pump Inhibitors Market Facts & Figures by Country

3.3.1 North America Proton Pump Inhibitors Sales by Country

3.3.2 North America Proton Pump Inhibitors Revenue by Country

3.3.3 United States

3.3.4 Canada

3.4 Europe Proton Pump Inhibitors Market Facts & Figures by Country

3.4.1 Europe Proton Pump Inhibitors Sales by Country

3.4.2 Europe Proton Pump Inhibitors Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Proton Pump Inhibitors Market Facts & Figures by Region

3.5.1 Asia Pacific Proton Pump Inhibitors Sales by Region

3.5.2 Asia Pacific Proton Pump Inhibitors Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 China Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.6 Latin America Proton Pump Inhibitors Market Facts & Figures by Country

3.6.1 Latin America Proton Pump Inhibitors Sales by Country

3.6.2 Latin America Proton Pump Inhibitors Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa Proton Pump Inhibitors Market Facts & Figures by Country

3.7.1 Middle East and Africa Proton Pump Inhibitors Sales by Country

3.7.2 Middle East and Africa Proton Pump Inhibitors Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Proton Pump Inhibitors Historic Market Analysis by Type

4.1 Global Proton Pump Inhibitors Sales Market Share by Type (2017-2022)

4.2 Global Proton Pump Inhibitors Revenue Market Share by Type (2017-2022)

4.3 Global Proton Pump Inhibitors Price by Type (2017-2022)

5 Global Proton Pump Inhibitors Historic Market Analysis by Distribution Channel

5.1 Global Proton Pump Inhibitors Sales Market Share by Distribution Channel (2017-2022)

5.2 Global Proton Pump Inhibitors Revenue Market Share by Distribution Channel (2017-2022)

5.3 Global Proton Pump Inhibitors Price by Distribution Channel (2017-2022)

6 Key Companies Profiled

6.1 Takeda

6.1.1 Takeda Corporation Information

6.1.2 Takeda Description and Business Overview

6.1.3 Takeda Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Takeda Proton Pump Inhibitors Product Portfolio

6.1.5 Takeda Recent Developments/Updates

6.2 Pfizer

6.2.1 Pfizer Corporation Information

6.2.2 Pfizer Description and Business Overview

6.2.3 Pfizer Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Pfizer Proton Pump Inhibitors Product Portfolio

6.2.5 Pfizer Recent Developments/Updates

6.3 AstraZeneca

6.3.1 AstraZeneca Corporation Information

6.3.2 AstraZeneca Description and Business Overview

6.3.3 AstraZeneca Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.3.4 AstraZeneca Proton Pump Inhibitors Product Portfolio

6.3.5 AstraZeneca Recent Developments/Updates

6.4 Bayer

6.4.1 Bayer Corporation Information

6.4.2 Bayer Description and Business Overview

6.4.3 Bayer Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Bayer Proton Pump Inhibitors Product Portfolio

6.4.5 Bayer Recent Developments/Updates

6.5 Sun Pharma

6.5.1 Sun Pharma Corporation Information

6.5.2 Sun Pharma Description and Business Overview

6.5.3 Sun Pharma Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Sun Pharma Proton Pump Inhibitors Product Portfolio

6.5.5 Sun Pharma Recent Developments/Updates

6.6 Teva

6.6.1 Teva Corporation Information

6.6.2 Teva Description and Business Overview

6.6.3 Teva Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Teva Proton Pump Inhibitors Product Portfolio

6.6.5 Teva Recent Developments/Updates

6.7 Eisai Co.

6.6.1 Eisai Co. Corporation Information

6.6.2 Eisai Co. Description and Business Overview

6.6.3 Eisai Co. Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Eisai Co. Proton Pump Inhibitors Product Portfolio

6.7.5 Eisai Co. Recent Developments/Updates

6.8 Mylan

6.8.1 Mylan Corporation Information

6.8.2 Mylan Description and Business Overview

6.8.3 Mylan Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Mylan Proton Pump Inhibitors Product Portfolio

6.8.5 Mylan Recent Developments/Updates

6.9 AOSAIKANG Pharma

6.9.1 AOSAIKANG Pharma Corporation Information

6.9.2 AOSAIKANG Pharma Description and Business Overview

6.9.3 AOSAIKANG Pharma Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.9.4 AOSAIKANG Pharma Proton Pump Inhibitors Product Portfolio

6.9.5 AOSAIKANG Pharma Recent Developments/Updates

6.10 Luoxin Pharma

6.10.1 Luoxin Pharma Corporation Information

6.10.2 Luoxin Pharma Description and Business Overview

6.10.3 Luoxin Pharma Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.10.4 Luoxin Pharma Proton Pump Inhibitors Product Portfolio

6.10.5 Luoxin Pharma Recent Developments/Updates

6.11 LIVZON

6.11.1 LIVZON Corporation Information

6.11.2 LIVZON Proton Pump Inhibitors Description and Business Overview

6.11.3 LIVZON Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.11.4 LIVZON Proton Pump Inhibitors Product Portfolio

6.11.5 LIVZON Recent Developments/Updates

6.12 Eastchina Pharma

6.12.1 Eastchina Pharma Corporation Information

6.12.2 Eastchina Pharma Proton Pump Inhibitors Description and Business Overview

6.12.3 Eastchina Pharma Proton Pump Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.12.4 Eastchina Pharma Proton Pump Inhibitors Product Portfolio

6.12.5 Eastchina Pharma Recent Developments/Updates

7 Proton Pump Inhibitors Manufacturing Cost Analysis

7.1 Proton Pump Inhibitors Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Proton Pump Inhibitors

7.4 Proton Pump Inhibitors Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Proton Pump Inhibitors Distributors List

8.3 Proton Pump Inhibitors Customers

9 Proton Pump Inhibitors Market Dynamics

9.1 Proton Pump Inhibitors Industry Trends

9.2 Proton Pump Inhibitors Market Drivers

9.3 Proton Pump Inhibitors Market Challenges

9.4 Proton Pump Inhibitors Market Restraints

10 Global Market Forecast

10.1 Proton Pump Inhibitors Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of Proton Pump Inhibitors by Type (2023-2028)

10.1.2 Global Forecasted Revenue of Proton Pump Inhibitors by Type (2023-2028)

10.2 Proton Pump Inhibitors Market Estimates and Projections by Distribution Channel

10.2.1 Global Forecasted Sales of Proton Pump Inhibitors by Distribution Channel (2023-2028)

10.2.2 Global Forecasted Revenue of Proton Pump Inhibitors by Distribution Channel (2023-2028)

10.3 Proton Pump Inhibitors Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Proton Pump Inhibitors by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Proton Pump Inhibitors by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample